TriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping Technology

Rhea-AI Summary

TriLink BioTechnologies, a Maravai LifeSciences company, has entered into a non-exclusive License and Supply Agreement with Lonza for its CleanCap mRNA capping technology. This agreement will allow Lonza to use TriLink's patented cap analogs for mRNA development and manufacturing services, enhancing the accessibility of CleanCap technology in the industry. CleanCap technology offers high capping efficiency and streamlines mRNA production processes, contributing to improved mRNA function and increased capped material yield.

Positive

• TriLink BioTechnologies has expanded access to its CleanCap mRNA capping technology through the agreement with Lonza, potentially leading to increased adoption and utilization of CleanCap technology in the industry.

• CleanCap technology has shown to enhance mRNA function, streamline manufacturing processes, and maximize capped material yield, indicating potential efficiency improvements in mRNA production and development programs.

• TriLink's introduction of CleanCap M6, its most robust CleanCap analog to date, has demonstrated increased mRNA expression by over 30% compared to enzymatic capping methods, suggesting improved performance and efficacy in mRNA applications.

Negative

• While the agreement with Lonza enhances the accessibility of CleanCap technology, it is non-exclusive, potentially leading to competition from other providers offering similar mRNA capping solutions in the market.

• Although CleanCap technology has been successful in advancing the mRNA capping industry and is used in approved vaccines, there may be challenges in maintaining a competitive edge as other technologies emerge in the field.

Lonza customers can now access TriLink’s CleanCap^® mRNA capping technology for non-commercial use, enabling further development of critical mRNA therapeutics

SAN DIEGO--(BUSINESS WIRE)-- TriLink BioTechnologies (TriLink^®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries. This agreement with Lonza strengthens TriLink’s objective to drive greater access to CleanCap^® mRNA capping technologies as the demand for mRNA – a promising therapeutic modality – continues to grow.

According to the terms of the agreement, TriLink^® will supply its patented CleanCap^® M6, CleanCap^® AG 3’OMe, CleanCap^® AG, and CleanCap^® AU cap analogs for use in Lonza’s global mRNA development and manufacturing services, from pre-clinical through Phase III programs. CleanCap^® technology is a one-pot solution with over 95% capping efficiency that streamlines mRNA production processes when compared to legacy capping methods.

“CleanCap^® technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield,” shared Drew Burch, President of Nucleic Acid Production at TriLink. “We’re thrilled to offer our innovative capping solutions to Lonza and its customers.”

Since its launch in 2017, TriLink’s CleanCap^® capping technology has continued to advance the mRNA capping industry and is used in a majority of approved mRNA and saRNA vaccines. In May 2023, TriLink introduced its most robust CleanCap analog to date, CleanCap^® M6, with studies indicating increased mRNA expression by more than 30% versus enzymatic capping methods.

About TriLink BioTechnologies

TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap^® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.

For more information, visit trilinkbiotech.com.

About Maravai LifeSciences

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

For more information about Maravai LifeSciences, visit maravai.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240430716807/en/

Liz Robinson of CG Life

TriLink BioTechnologies

lrobinson@cglife.com

312-997-2436

Source: TriLink BioTechnologies

FAQ

What is the agreement between TriLink BioTechnologies and Lonza?

TriLink BioTechnologies and Lonza have entered into a non-exclusive License and Supply Agreement for TriLink's CleanCap mRNA capping technology.

What benefits does CleanCap technology offer?

CleanCap technology provides high capping efficiency, streamlines mRNA production processes, improves mRNA function, and increases capped material yield.

What is CleanCap M6?

CleanCap M6 is TriLink's latest CleanCap analog, showing over 30% increased mRNA expression compared to enzymatic capping methods.